FibroGen's Roxadustat Shows A Clear Positive Phase III MACE Result, But Future Sales Remain Uncertain Seeking Alpha, 22 May 2019 Summary FibroGen’s stock price recently experienced a big drop after the release of its Phase III MACE result.